Roman Tsubin / Shutterstock.com
The proliferation of brands, combined with the financial and PR consequences of a potential rebrand in the event of infringement, has made selecting a trademark trickier than ever. Christina Martini and Virginia Wolk Marino of DLA Piper report.
In the challenging and complex world of life sciences product development, choosing a brand name that survives numerous trademark office and regulatory clearance processes is essential.
An effective pharmaceutical or medical product name can become a significant source of value to companies in this industry, and can serve to both differentiate a product and engender loyalty in a competitive market.
Given the high stakes, pharma companies often retain specialists to help compile lists of names for global legal consideration and brand clearance, a process that usually entails several rounds of searching and often includes both preliminary and more in-depth analyses. Preliminary trademark searches provide a review of nearly identical trademark applications and registrations.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Christina Martini,Virginia Wolk Marino, DLA Piper, trademark, brands, USANs, FDA, INNs, life sciences,